Edward L. Field
Keine laufenden Positionen mehr
Karriereverlauf von Edward L. Field
Ehemalige bekannte Positionen von Edward L. Field
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIORESTORATIVE THERAPIES, INC. | Corporate Officer/Principal | 17.02.2015 | 24.07.2017 |
| NUO THERAPEUTICS, INC. | Geschäftsführer | 08.02.2012 | 30.06.2014 |
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Geschäftsführer | 01.01.2004 | 24.02.2010 |
| Corporate Officer/Principal | 24.02.2010 | 18.10.2010 | |
| Präsident | 01.01.2004 | 24.02.2010 | |
| Inologic, Inc. | Präsident | - | 01.09.2004 |
| Molecumetics Ltd. | Präsident | - | 01.01.2002 |
Ausbildung von Edward L. Field
| Duke University | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| President | 3 |
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NUO THERAPEUTICS, INC. | Health Technology |
| BIORESTORATIVE THERAPIES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
| Inologic, Inc. | |
| Molecumetics Ltd. |
- Börse
- Insiders
- Edward L. Field
- Erfahrung
